SCHEDULE 13G/A: Rosalind Advisors and Affiliates Disclose 9.9% Stake in PolyPid Ltd. via Amended Schedule 13G Filing

Rosalind Advisors, Inc., along with its affiliates Steven Salamon, Gilad Aharon, and Rosalind Master Fund L.P., have disclosed a combined beneficial ownership of 9.9% in PolyPid Ltd., totaling 4,085,588 common shares, as detailed in an amended Schedule 13G filing.

Summary

• Rosalind Advisors, Inc., Rosalind Master Fund L.P., Steven Salamon, and Gilad Aharon collectively reported beneficial ownership of 4,085,588 common shares of PolyPid Ltd. as of December 31, 2024.
• This represents 9.9% of PolyPid Ltd.'s common stock, calculated based on 11,234,575 ordinary shares outstanding as of January 17, 2025, as per the issuer's 6K filing.
• The reported aggregate ownership includes 1,022,521 shares of common stock and 3,063,067 shares issuable upon the exercise of pre-funded and regular warrants.
• A 'blocker provision' in the warrants prevents their exercise if it would result in beneficial ownership by the holder exceeding 9.99% of the Common Stock.
• Consequently, as of the event date (December 31, 2024), the reporting persons were unable to exercise any of the warrants due to these blocker provisions, meaning their actual beneficial ownership after giving effect to such blockers is less than the reported aggregate amount.
• The shared voting and dispositive power for each reporting person is 1,022,521 shares, reflecting the shares not subject to the blocker provision.
• Rosalind Advisors Inc. serves as the investment advisor to Rosalind Master Fund L.P.
• Steven Salamon is the President and portfolio manager of Rosalind Advisors Inc., and Gilad Aharon is a portfolio manager and member of Rosalind Advisors Inc.

Sentiment

Score: 5

Explanation: The document is a factual disclosure of beneficial ownership and does not contain subjective language or forward-looking statements that would indicate a positive or negative sentiment.

Positives

• Increased transparency regarding significant institutional ownership in PolyPid Ltd.
• The presence of a significant institutional investor like Rosalind Advisors may signal confidence in the company's long-term prospects.

Negatives

• The 'blocker provision' on warrants limits the immediate ability of the reporting persons to fully convert their potential stake, which could restrict their influence or increase their direct shareholding.

Risks

• The existence of 'blocker provisions' on warrants means that the reported potential ownership (including warrants) is not fully exercisable if it would push the beneficial ownership above 9.99%, potentially limiting the investor's flexibility or influence over the issuer.

Future Outlook

NA

Industry Context

This filing reflects a significant institutional investment in PolyPid Ltd., a company in the biotechnology or pharmaceutical sector, indicating continued investor interest in companies within this industry. Such disclosures are standard for large equity positions and do not inherently reflect broader industry trends beyond general investor activity.

Stakeholder Impact

• Shareholders: Provides transparency regarding a significant institutional investor's stake, which can influence market perception and potentially stock liquidity.
• Company Management: Awareness of a large shareholder's position may influence strategic decisions or engagement with the investor.

Key Dates

Keywords

PolyPid Ltd., Schedule 13G, beneficial ownership, institutional investor, warrants, common shares, Rosalind Advisors, Rosalind Master Fund, SEC filing, equity stake, shareholding, M8001Q126